IRulya Therapeutics Inc. Company Profile
NASDAQ: IRLAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IRulya Therapeutics at a glance
IRulya Therapeutics Inc. (NASDAQ: IRLA) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in New Haven, CT. IRulya Therapeutics is led by Dr. Brigette Roberts M.D. and employs about 38 people. The company's shares have traded publicly since 2019.
At a market capitalization of $433.0 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001662774, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does IRulya Therapeutics do?
IRulya Therapeutics Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidate comprises eDSP, which is in Phase 3 for the treatment of rare pediatric neurodegenerative diseases, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene. Its AIDE technology platform is a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells and consists of automated equipment, the RCL, a sterile single-use consumable treatment kit comprising medical device kits, syringe kits, and process solutions. IRulya Therapeutics Inc. was formerly known as Quince Therapeutics, Inc. and changed its name to IRulya Therapeutics Inc. in October 2026. The company was incorporated in 2012 and is headquartered in New Haven, Connecticut.
Business description based on the company's public filings.
Company information
- Legal name
- IRulya Therapeutics Inc.
- Ticker
- NASDAQ: IRLA
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Brigette Roberts M.D.
- Employees
- 38
- Headquarters
- 101 College Street, New Haven, CT, United States
- Phone
- 415 910 5717
- Website
- irulya.com
- IPO year
- 2019
- Market cap
- $433.01M
- SEC CIK
- 0001662774
- Latest annual report
- 10-K · Apr 10, 2026
Companies similar to IRulya Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PROKProKidney Corp. Class A | 1.04 | -1.89% | $415.21M | vs IRLA |
| TECXTectonic Therapeutic Inc. | 20.73 | -1.47% | $405.26M | vs IRLA |
| TVGNTevogen Inc. | 5.90 | -6.35% | $405.20M | vs IRLA |
| FENCFennec Pharmaceuticals Inc. | 13.09 | -2.68% | $462.14M | vs IRLA |
| CADLCandel Therapeutics Inc. | 5.04 | -1.75% | $395.37M | vs IRLA |
| RGNXREGENXBIO Inc. | 7.16 | -0.28% | $473.44M | vs IRLA |
| SANASana Biotechnology Inc. | 1.59 | -8.62% | $476.42M | vs IRLA |
| DNAGinkgo Bioworks Holdings Inc. Class A | 7.46 | -9.02% | $483.54M | vs IRLA |